Septerna, Inc.
SEPN · Nasdaq · USD · Market cap $1.9B · 130 employees
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price38.61 USD at the 20 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 20 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 1.39)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $51.00 to $65.00, base estimate $60.00 (screen dated 2026-11-20).
- Trend Markup
- Insiders insiders sold, $807,015, latest filing 2026-11-12
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 1.39, read 2026-11-20
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Septerna, Inc. holds its Markup at $38.61. Consolidating, no directional conviction, held for 329 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 329 days |
| Price at the screen | $38.61 |
| Valuation | N/A trailing · -25.81 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 2.20 |
Five Screens: SEPN's Results
FAIL. Revenue purity
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 3.96% | Below 33% | Pass |
| Interest-bearing cash | 26.43% | Below 33% | Pass |
| Receivables | 21.99% | Below 49% | Pass |
| Revenue purity | 42.50% | Below 5% | Fail |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Septerna, clears the business-activity screen, and its debt is inside the line. Where it falls short is income purity: around 43% of its income right now is interest earned on a large cash position, against a roughly 5% ceiling, so it does not pass. That reflects what it earns today, not the business itself, and it could clear the screen if its operating revenue grows and the interest share falls.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when SEPN's ethical verdict changes
Today SEPN does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 36% discount to our $60.00 fair value.
USD, 2026-11-20 screen. A 35.6% under base.
Street: 9 covering, consensus Strong Buy. Average target +55%.
Early stage bet on unproven oral drugs
A promising lab compound only matters once it survives years of trials and reaches patients who can actually take it as a pill. Septerna sits at that early point, chasing GPCR targets in endocrinology and inflammation with nothing yet on the market. The opportunity rating sits at none despite the analyst target and the headline margin of safety, because the business remains pre-revenue in any meaningful sense and carries the classic clinical-stage uncertainties.
Revenue has jumped from a negligible base, yet the firm still posts a fifty percent negative profit margin and negative return on equity. The forward multiple looks extreme because there are no earnings to measure against. Strong buy ratings from nine analysts reflect hope rather than proof, and an unknown moat leaves the company exposed to larger players that can replicate or outspend.
Risk sits around the usual biotech traps of trial failure, repeated cash raises, and binary outcomes that can wipe out value overnight. Currency and regulatory shifts add further noise. Analysis, not advice.
| Forward P/E | -25.8x |
| EPS, trailing | -1.30 |
| EPS, forward | -1.52 |
| Revenue growth | -12.2%revenue is shrinking |
| Profit margin | -61.3%currently unprofitable |
| Return on equity | -14.4%not currently earning a positive return on equity |
| FCF yield | -0.42% |
| Debt to equity | 0.05minimal debt: a conservative balance sheet |
| Current ratio | 4.84comfortably covers its short-term bills |
| Beta | 2.20much more volatile than the market |
| Short interest, float | 0.13% |
| 52-week range | 22.78 - 53.34 |
| Market cap | $1.9B |
| Employees | 130 |
SEPN-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from accumulation to markup since the last review. Since the last review it dropped out of the Titan Ethical 500.
Earnings landed in this window. Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- Septerna (SEPN) Stock Sees Fair Value Lift As Analysts Raise SEP 479 Expectations Yahoo Finance · 8d ago
- What Septerna Shares Profit To Loss Swing Means For Shareholders Yahoo Finance · 11d ago
- Septerna, Inc. (SEPN) Reports Q3 Loss, Lags Revenue Estimates Yahoo Finance · 12d ago
- Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial Results Yahoo Finance · 12d ago
- Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting Yahoo Finance · 17d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-12 | Finer Jeffrey | CEO | S - Sale+OE | 18,500 | $807,015 |
| 2026-11-11 | Ezekowitz Alan | Dir | S - Sale | 81,820 | $3,934,363 |
| 2026-10-15 | Bhatt Elizabeth | Pres, COO | S - Sale+OE | 4,000 | $149,644 |
| 2026-08-12 | Third Rock Ventures V, L.P. | 10% | S - Sale | 147,200 | $7,399,858 |
| 2026-08-12 | Ra Capital Management, L.P. | Dir, 10% | S - Sale | 1,493,000 | $63,452,500 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $23.57 | +29.3% | · | $1,293 | +29.3% |
| 2 months | $23.09 | +32.0% | · | $1,320 | +32.0% |
| 3 months | $26.44 | +15.2% | · | $1,152 | +15.2% |
| 6 months | $26.21 | +16.3% | · | $1,163 | +16.3% |
| 1 year | $10.28 | +196.4% | · | $2,964 | +196.4% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever SEPN does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.